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HIV-1 expresses several accessory proteins to coun-
teract host anti-viral restriction factors to facilitate
viral replication and disease progression. One such
protein, Vpr, has been implicated in affecting multi-
ple cellular processes, but its mechanism remains
elusive. Here we report that Vpr targets TET2 for pol-
yubiquitylation by the VprBP-DDB1-CUL4-ROC1 E3
ligase and subsequent degradation. Genetic inacti-
vation or Vpr-mediated degradation of TET2 en-
hances HIV-1 replication and substantially sustains
expression of the pro-inflammatory cytokine inter-
leukin-6 (IL-6). This process correlates with reduced
recruitment of histone deacetylase 1 and 2 to the
IL-6 promoter, thus enhancing its histone H3
acetylation level during resolution phase. Blocking
IL-6 signaling reduced the ability of Vpr to enhance
HIV-1 replication. We conclude that HIV-1 Vpr
degrades TET2 to sustain IL-6 expression to
enhance viral replication and disease progression.
These results suggest that disrupting the Vpr-
TET2-IL6 axis may prove clinically beneficial to
reduce both viral replication and inflammation
during HIV-1 infection.
INTRODUCTION
Human immunodeficiency virus 1 (HIV-1) expresses multiple
accessory proteins, including viral protein R (Vpr), to counteract
host restriction inhibitors (Simon et al., 2015; Strebel, 2013). The
functional importance of Vpr to viral propagation was initially
shown in rhesus macaque infection using Vpr-deficient SIV,
which exhibited a decrease in viral replication and delay inAIDS disease progression (Lang et al., 1993). In the humanized 
mouse model, Vpr enhances acute HIV-1 infection (Sato et al., 
2013). Vpr has been shown to affect several cellular processes 
of host cells, including cell cycle, DNA damage response, and 
apoptosis (Romani and Cohen, 2012). However, it remains 
unclear how a change in these host cellular processes by Vpr 
facilitates HIV-1 replication.
A number of reports support that Vpr facilitates HIV-1 repli-
cation through its interaction with VprBP (Simon et al., 2015; 
Strebel, 2013). Mutations in Vpr disrupting its binding with 
VprBP, such as Q65R, reduced cell-to-cell spread of HIV-1 
from macrophages to CD4+ T lymphocytes (Collins et al., 
2015) or the ability of HIV-1 to escape from innate immune 
sensing (Laguette et al., 2014). VprBP binds near-stoichiomet-
rically with DNA damage-binding protein (DDB1) and, via 
DDB1, with cullin 4 and small RING finger protein ROC1/
RBX1 to assemble a VprBP-DDB1-CUL4-RING (CRL4VprBP) 
E3 ubiquitin ligase complex (Jackson and Xiong, 2009). The 
finding that VprBP is a subunit of an E3 ligase complex has 
led to the identification of several host proteins targeted by 
Vpr for the ubiquitylation by the CRL4VprBP E3 ligase. These 
include base excision repair enzyme uracil DNA glycosylase 
(UNG2) (Ahn et al., 2010), telomerase catalytic subunit (TERT)
(Wang et al., 2013), DNA endonuclease end repair factor 
MUS81 (Laguette et al., 2014), DNA replication factor MCM10 
(Romani et al., 2015), transcription factor HLTF (Lahouassa 
et al., 2016), and histone deacetylases (HDACs) (Romani 
et al., 2016). Whether or how these factors inhibit HIV-1 replica-
tion is unclear; in particular, whether loss of function of any 
of these host genes rescues the replication of Vpr-deficient 
HIV-1 is yet to be determined.
In a search for the substrate of VprBP, we previously discov-
ered that it binds to the TET family of DNA dioxygenases 
and targets them for monoubiquitylation by the CRL4VprBP E3 
ligase to promote TET binding to chromatin (Nakagawa et al., 
2015). This finding led us to determine whether Vpr affects 
CRL4VprBP-mediated TET2 ubiquitylation.
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Figure 1. Vpr Promotes TET Protein Degradation in a VprBP-Dependent Manner
(A) Vpr decreases levels of TET2 protein, not mRNA. THP1 cells were transfected with plasmid expressing HA-Vpr. Western blots were performed with the
indicated antibodies, and mRNA level was analyzed by quantitative RT-PCR; error bars represent ± SD for triplicate experiments, n = 2.
(B) Vpr from different subtypes of HIV-1, HIV-2, and SIV, but not Vpx, decrease TET2 protein levels. HEK293T cells were transfected with the indicated plasmids,
and whole-cell extracts were prepared 24 hr after transfection, followed by immunoblotting analysis; n = 2.
(C) Wild-type but not Vpr-deficient HIV-1 infection leads to TET2 degradation. THP1 and PBMCs were infected with Vpr+ HIV-1 and Vpr HIV-1, and TET2 levels
were measured.
(D) THP1 cells were infected with HIV-1 in the presence of various HIV inhibitors. TET2 proteins were measured at 48 hr post-infection; n = 2.
(E) Virion-associated Vpr in virus-like particles (VLPs) degrades TET2. THP1 cells were treated with the indicated amount of VLP (as quantified by p24). TET2
proteins were analyzed 12 hr after treatment.
(F) Vpr-promoted TET2 degradation is Vpr-VprBP binding dependent.. Cells were transfected with indicated plasmids, followed by Flag-TET2 immunoblotting;
n = 2.
(G) Knocking down VprBP blocks Vpr-induced TET2 degradation. Cells were transfected with siRNA targeting VprBP for 48 hr and then treated with VLP-Vpr for
another 24 hr followed by immunoblotting with indicated antibodies; n = 2.RESULTS
HIV-1 Vpr Promotes TET2 Degradation in a VprBP-
Dependent Manner
To determine the effect of Vpr on TET2 protein, we first trans-
fected HIV-1 Vpr (Clade B) into human THP1 monocytic cells. 
We found, surprisingly, that the level of TET2 protein, but not 
mRNA, was significantly decreased (Figure 1A). Moreover, Vpr 
from HIV-1 clade A Q23, HIV-2 ROD9, and SIV-mac239 were 
all capable of decreasing TET2 proteins (Figure 1B), suggesting 
that targeting TET2 for degradation represents a conservedfunction of Vpr. Vpx, a homolog of Vpr that is encoded by
HIV-2 and most simian lentiviruses, also binds to VprBP and
targets a host restriction factor, SAMHD1, for ubiquitylation by
CRL4VprBP and subsequent degradation by the proteasome
(Hrecka et al., 2011; Laguette et al., 2011). We found that in
contrast to Vpr, expression of Vpx had no effect on TET2 protein
(Figures 1B and S1A), indicating a different specificity of Vpr from
Vpx in promoting host protein degradation. We also found
that Vpr can promote the degradation of both TET1 and TET3
(Figure S1B), indicating that Vpr promotes the degradation
of all three TET proteins. Since TET2 is the predominant TET
Figure 2. Vpr Reprograms CRL4VprBP E3 Ligase to Catalyze Polyubiquitylation of TET2
(A) Vpr-mediated TET2 degradation is blocked by the proteasome inhibitor, MG132. THP1 cells were transfected with HA-Vpr and then treated with inhibitors of
lysosome (NH4Cl, 20 mM), calpain (Calpeptin, 50 mM), caspase (Z-VAD-FMK, 100 mM), or 26S proteasome (MG132, 10 mM) for 24 hr, followed by immunoblotting
analyses; n = 2.
(legend continued on next page)
gene expressed in THP1 cells (Figure S1C), we therefore focused
on TET2 in this study.
To demonstrate TET2 degradation in HIV-1-infected cells, we
infected THP1 cells or human peripheral blood mononuclear
cells (PBMCs) with wild-type and Vpr-deficient mutant HIV-1
and examined the level of TET2 protein at different time points
after infection. TET2 protein levels decreased significantly after
infection by the wild-type but not the Vpr-deficient HIV-1 in
both cells (Figure 1C). To determine at which stage of the
HIV-1 life cycle Vpr promotes TET2 degradation, THP1 cells
were infected with HIV-1 in the presence of inhibitors of
viral fusion and entry (Enfuvirtide, T20), reverse transcriptase
(Nevirapine, NVP), integrase (Raltegravir, RAL), or protease
(Amprenavir, AMP). Only the fusion inhibitor inhibited TET2
degradation (Figure 1D), indicating that the virion-associated
Vpr is sufficient to degrade TET2 protein soon after viral entry,
and de novo Vpr protein production is not required for this
function. Supporting this notion, we found TET2 is rapidly
degraded by Vpr as early as 6 hr after HIV-1 infection (Fig-
ure S1D). In addition, we generated virus-like particles (VLPs)
carrying HIV-1 Vpr and found, consistently, that virion-associ-
ated Vpr can induce TET2 degradation after addition to THP1
cells (Figure 1E).
To determine if VprBP is involved in the Vpr-mediated TET2
degradation, we generated Vpr Q65R mutant, which cannot
bind with VprBP (Figure S1E), and tested its effect on TET2
degradation. The results showed that Q65R mutation abolished
the ability of Vpr to promote TET2 degradation (Figure 1F).
Consistently, knocking down VprBP blocked the Vpr-induced
TET2 degradation (Figure 1G). These results demonstrate that
HIV-1 Vpr promotes TET2 degradation in a VprBP-dependent
manner.
Vpr Reprograms CRL4VprBP E3 Ligase to Catalyze
Polyubiquitylation of TET2
Two proteolytic cleavages, one by caspase (Ko et al., 2013)
and one by the calpain family of calcium-dependent proteases
(Wang and Zhang, 2014), have previously been shown to cleave
TET proteins. We treated Vpr-expressing THP1 cells with inhib-
itors of caspase, calpeptin, and lysosome and found that none
of them affected Vpr-promoted TET2 degradation (Figure 2A).
Instead, treatment with MG132, an inhibitor of the 26S pro-
teasome, effectively blocked TET2 reduction, indicating that
Vpr promotes TET2 degradation via the proteasomal pathway.(B) Wild-type but not Q65R mutant Vpr promotes TET2 polyubiquitylation in vi
prepared under denaturing conditions, and TET2 ubiquitylation was examined b
(C) Knockdown of individual components of the CRL4VprBP E3 ligase complex i
indicated plasmids and siRNA targeting the indicated genes for 72 hr. In vivo TET
conditions; n = 2.
(D) Wild-type but not VprBP-binding-deficient Q65R mutant Vpr promotes TET2
VprBP immune-complex and purified wild-type or Q65R mutant Vpr. Reactions w
indicated antibodies; n = 2.
(E) Vpr-promoted TET2 degradation by the CRL4VprBP E3 ligase is not depende
HEK293T cells were transfected with the plasmids indicated, and TET2 levels we
(F) Vpr alters TET2-VprBP interaction. HEK293T cells were transfected with indic
Chromo, chromo-like domain; LisH, homology to Lis1; n = 2.
(G) Q65Rmutant Vpr cannot bind VprBP to bridge TET2 binding to the C-terminal
protein-protein interactions were determined by IP-western analysis; n = 2.Consistent with this notion, MG132 treatment accumulated pol-
yubiquitylated TET2 in cells expressing Vpr, but not Vpr Q65R
mutant (Figure 2B) or Vpx (Figure S2A).
To test if Vpr promoted TET2 ubiquitylation via VprBP-based
CRL4VprBP E3 complex, we knocked down individual compo-
nents of CRL4VprBP E3 ligase by siRNA in Vpr-expressing
cells and determined TET2 polyubiquitylation. Knocking down
either VprBP or DDB1 substantially reduced the ubiquitylation
of TET2 in cells (Figure 2C). Note that VprBP was downregu-
lated when DDB1 was targeted by the siRNA, as DDB1 is the
major binding protein of VprBP and the binding stabilizes
VprBP as we observed previously (Nakagawa et al., 2015).
Knockdown of either CUL4A or CUL4B partially reduced
TET2 polyubiquitylation, while simultaneous knockdown of
both CUL4A and CUL4B almost completely inhibited TET2 pol-
yubiquitylation (Figure 2C). In vitro, incubation of immunopuri-
fied TET2 with a CRL4VprBP immune complex resulted in robust
TET2 polyubiquitylation in the presence of Vpr (Figure 2D),
which is dependent on the addition of E1, E2, and ubiquitin
(Figure S2B). These results demonstrate that Vpr-promoted
TET2 degradation is mediated by CRL4VprBP E3 ligase via the
26S proteasome.
CRL4VprBP, in the absence of Vpr, catalyzes TET2 monoubi-
quitylation on K1299 (Nakagawa et al., 2015). We found
that mutations in TET2 disrupting the monoubiquitylation site
(K1212N or K1212E of mouse Tet2, corresponding to human
K1299N or K1299E) or abolishing monoubiquitylation (C1211Y
in mouse Tet2, corresponding to C1298Y in human TET2)
did not affect Vpr-promoted TET2 degradation (Figure 2E),
suggesting that Vpr is unlikely to be acting as a processivity
or chain-elongation factor to extend the monoubiquitylation
at K1299 to a polyubiquitin chain. We also found that F1213S
mutation (corresponding to F1300S in human TET2) that dis-
rupts its binding with VprBP had little effect on Vpr-promoted
TET2 degradation (Figure 2E). On the other hand, the Q65R
mutation abolished the ability of Vpr to promote TET2 degrada-
tion (Figure 1F) and to promote TET2 polyubiquitylation either
in cells (Figure 2B) or in vitro (Figure 2D). These results
indicate that Vpr-promoted polyubiquitylation by CRL4VprBP
E3 ligase may involve a change of the VprBP-TET2 binding.
In the absence of Vpr, TET2 binds to a sequence within the
N-terminal 909 residues of VprBP (1–909, N909), but not the
C-terminal region of VprBP (918–1507, C590). The expression
of wild-type Vpr (but not Q65R mutant), however, enabledvo. Cells were transfected with indicated plasmids. Whole-cell lysates were
y coupled IP-western; n = 2.
nhibits Vpr-promoted TET2 ubiquitylation in vivo. Cells were transfected with
2 ubiquitylation was determined by IP-western blot analysis under denaturing
polyubiquitylation in vitro. Immunopurified TET2 protein was incubated with
ere terminated by adding SDS loading buffer followed by immunoblotting with
nt on either the monoubiquitylation site in TET2 or the VprBP-TET2 binding.
re determined by western blot.
ated plasmids followed by IP-western analysis with the indicated antibodies.
portion of VprBP. HEK293T cells were transfected with indicated plasmids, and
TET2 to bind the VprBP-C590 (Figures 2F and 2G), indicating
that Vpr changes TET2-VprBP binding and tethers TET2 to
a different binding site in the C-terminal region of VprBP. This
is consistent with the structural analyses showing that Vpr
and Vpx bridge the binding of substrate UNG2 or SAMHD1 to
a sequence (residues 1050–1396) within the C-terminal region
of VprBP (Schwefel et al., 2014; Wu et al., 2016). Structural
analysis of SAMHD1-Vpx-VprBP/DCAF1 complex suggests
that Vpx places SAMHD1 in the proximity of the ROC1 RING
domain, ideally located for ubiquitin transfer. Our study pro-
vides a clear example where the switch between mono-
ubiquitylation and polyubiquitylation, which lead to different
paths of protein function, can be achieved by a single factor.
Further structural studies would not only gain insight into
the mechanism of Vpr, but also monoubiquitylation versus
polyubiquitylation.
Genetic Inactivation of TET2 Enhances HIV-1
Replication
Vpr is known to increase HIV-1 replication in myeloid cells (Con-
nor et al., 1995). We found that ectopic expression of TET2
significantly inhibited HIV-1 replication in THP1 cells (Figure 3A).
Next, we generated TET2 knockout THP1 cells using the
CRISPR-Cas9 system (Figures 3B and S3A). Deletion of TET2
did not noticeably affect THP1 cell proliferation (Figure S3B),
but significantly increased HIV-1 infection at different multiplic-
ities of infection (MOIs), as measured by FACS analysis of intra-
cellular p24 expression (Figures 3C and S3C). TET2 deletion also
increased HIV-1 viremia in the cellular supernatant as measured
by p24 ELISA over multiple rounds of infection (Figures 3D
and S3D).
To confirm the inhibitory effect of TET2 toward HIV and
exclude the off-target effects associated with the CRISPR-
Cas9 system, we performed a rescue experiment by ectopically
expressing either full-length or the cysteine-rich dioxygenase
(CD) domain of TET2 in TET2-KO THP1 cells. By expressing
different amounts of TET2, we found that ectopically expressed
TET2 inhibited HIV-1 infection in a dose-dependent manner and
that this inhibition was counteracted by Vpr (Figure S3E).
Expression of either the full-length or CD domain of TET2 re-
sulted in near-complete restoration of inhibition on HIV-1 (Fig-
ure 3E), while the catalytic inactivating mutant in the context
of either full-length or CD domain of TET2 partially restored
the inhibition of HIV-1 infection. These results suggest that
TET2-mediated inhibition of HIV-1 involves both catalytic-
dependent and -independent mechanisms. Notably, the func-
tion of TET2 in inhibiting HIV-1 was abolished by the infection
of Vpr+ HIV-1 (Figure S3F).
To confirm the inhibitory activity of TET2 toward HIV-1 in
primary human cells, we knocked down TET2 in primary hu-
man monocyte-derived-macrophages (MDMs) by two different
shRNAs. HIV-1 replication was significantly enhanced after
TET2 knockdown inMDMs (Figures 3F and S3G). We also tested
the effect of TET2 degradation on Vpr-enhanced HIV-1 replica-
tion in macrophages. HIV-1 or HIV-1DVpr were used for infection
in shCTRL and shTET2-treated MDMs, and levels of p24 in the
supernatant were assessed. Vpr enhanced HIV-1 replication
12- to 15-fold in control cells but only 4- to 5-fold in TET2 knock-down cells (Figure S3H), indicating that TET2 is an important, but
not the only, target of Vpr to enhance HIV-1 replication.
Vpr Degrades TET2 to Enhance HIV-1 Replication
Independently of G2 Cell-Cycle Arrest
One notable alteration of cellular function by Vpr is the induction
of G2 cell-cycle arrest, but its cause and functional relevance to
HIV-1 replication remains unclear (Romani and Cohen, 2012).
Deletion of TET2 did not affect the cell-cycle phase distribution,
and Vpr caused similar G2 cell-cycle arrest in both control and
TET2-KO cells (Figure S4A), indicating that TET2 does not play
a significant role in cell-cycle control and is not required for
Vpr-induced G2 arrest. We then established a THP1 cell-stable
cell line with tetracycline-inducible expression of Vpr (THP1/
Tet-Vpr) and induced Vpx expression at different stages of the
cell cycle. We found that Vpr degrades TET2 with an indistin-
guishable efficiency in cells at different phases of the cell cycle
(Figure S4B), suggesting that Vpr-promoted TET2 degradation
is not linked to a specific cell-cycle phase such as G2/M
population.
To determine functionally whether Vpr-enhanced HIV-1 repli-
cation is genetically linked to TET2 degradation and/or G2/M
cell-cycle arrest, we characterized a single amino acid substitu-
tion mutant of Vpr, R80A. Unlike the Q65R mutation, which dis-
rupts Vpr’s ability to bind with VprBP, to cause G2/M cell-cycle
arrest, and to enhance HIV-1 replication, the VprR80A mutant is
reported to be defective in causing G2 arrest (DeHart et al.,
2007) but retains Vpr’s activity of binding with VprBP and
enhancing viral replication (Rajan et al., 2006) (our confirmatory
results in Figures S4C and S4D). We found that VprR80A is active
to promote TET2 degradation (Figure 4A) and, importantly,
retains the ability to enhance HIV-1 replication similar to wild-
type Vpr when delivered into target cells via VLP (Figures 4B
and S4E). These results indicate that the two functions of Vpr
in promoting TET2 degradation and causing G2/M cell-cycle
arrest are genetically separable and that TET2 degradation, but
not G2/M cell-cycle arrest, is linked to the enhancement of
HIV-1 replication.
Vpr Degrades TET2 to Sustain IL-6 Expression and
Enhance HIV-1 Replication
Persistent inflammation is a hallmark of HIV-1 pathogenesis and
is linked to enhanced viral replication, but the mechanism that
leads to persistent inflammation remains elusive (Deeks et al.,
2013). It was recently reported that during inflammation resolu-
tion phase Tet2 was recruited by IkBz to IL-6 promoter, and
Tet2 in turn recruits HDAC1/2 to actively repress the transcrip-
tion of IL-6 (Zhang et al., 2015), a pleiotropic cytokine that has
pro- and anti-inflammatory properties and the increased levels
of which have been associated with HIV-1 disease progression
risk (Connolly et al., 2005). We hypothesized that Vpr, via
degrading TET2, may block the HDAC recruitment to the IL-6
gene, thereby maintaining elevated levels of IL-6 and contrib-
uting to persistent inflammation. To test this idea, we produced
VSV-G pseudotyped HIV-1-expressing luciferase (HIV-luc) com-
plemented with empty vector (HIV-lucDVpr), Flag-tagged wild-
type (HIV-luc+Vpr), or Q65R and R80A mutant Vpr and infected
primary human MDMs from different donors. We detected
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Figure 3. TET2 Inhibits HIV-1 Replication
(A) Overexpression of TET2 inhibits HIV-1 replication. THP1 cells were transfected with TET2 for 24 hr and then infected with HIV-1 (Vpr)/HSA reporter virus at
MOI of 0.1. Viral replication was analyzed by HSA reporter expression; n = 2. Error bars represent ± SD for triplicate experiments.
(B) CRISPR-Cas9-mediated knockout of TET2 in THP1 cells. CTRL cells were transduced by non-targeting gRNA; n = 2.
(C) TET2 deletion enhances HIV-1 replication. Control and TET2-KO THP1 cells were infected with HIV-1 (Vpr, MOI = 0.05). A percentage of infected cells were
analyzed at 2 days post infection (dpi) by intracellular p24 FACS (left panel). Different HIV-1 MOIs were used to infect control and TET2-KO THP1 cells and
analyzed by intracellular p24 FACS (right panel). Error bars represent ± SD for triplicate experiments.
(D) HIV-1 infection and replication kinetics in HIV-1 (Vpr)-infected control and TET2 knockout THP1 cells were measured over 9 days by p24 ELISA. This
experiment was repeated twice with same clone and once with another TET2 KO clone; n = 2. Error bars represent ± SD for triplicate experiments.
(E) Re-expression of TET2 in TET2-KO THP1 cells restored HIV-1 inhibition. Empty vector or vector expressing wild-type or mutant TET2 (1 mg) was transfected
into parental or TET2-KO cells, and protein expression was verified by western blot 24 hr after transfection. The transfected cells were infected with HIV-1 (Vpr),
and virus replication was analyzed by p24 ELISA at 6 dpi; n = 2. Error bars represent ± SD for triplicate experiments.
(F) TET2 inhibits HIV-1 replication in human primarymacrophages. TET2was knocked down by shRNA inMDMs, and the knockdown efficiency was confirmed by
RT-qPCR. MDMs were then infected with a macrophage-tropic HIV-1 (Vpr), and viral replication was analyzed by p24 FACS or p24 ELISA (donor n = 3).
Statistical analysis was performed using Student’s t test. *, **, and *** indicate a p value of less than 0.05, 0.01, or 0.001, respectively. n.s. = not significant. Error
bars were calculated from technical replicates.significantly higher production of IL-6 in MDMs infected with 
HIV-luc +Vpr or VprR80A when compared with MDMs infected 
with HIV-lucDVpr or +VprQ65R (Figures 4C, S4F, and S4G). The 
ability of Vpr to increase IL-6 levels is disrupted by the Q65R 
but not the R80A mutation, indicating that Vpr can elevate IL-6 
expression and that this function of Vpr is dependent on its bind-
ing with VprBP but not G2/M cell-cycle arrest. Kinetic studiesindicate that Vpr-induced IL-6 mRNA in MDMs occurs during
the resolution but not induction phase (Figures 4D and S4H).
We performed similar experiments in THP1 cells and found
that infection of HIV-luc+Vpr virus caused an IL-6 increase
similar to HIV-luc+VprQ65R virus during early infection, with a
somewhat faster kinetics than that seen in MDMs (Figure 4E),
but sustained a higher IL-6 expression during late resolution
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Figure 4. Vpr Degrades TET2 to Sustain IL-6 Expression and Enhance HIV-1 Replication
(A) Vpr R80A mutant promotes TET2 degradation. Flag-TET2 protein levels were analyzed 24 hr after transfection with indicated plasmids by western blot, n = 2.
(B) Separation of Vpr-mediated TET2 degradation andHIV-1 replication enhancement fromG2 arrest. VLPs incorporated with wild-type or Vprmutants Q65R and
R80A were generated and quantified by p24 ELISA. THP1 cultures were treated with equal amounts of VLPs (based on p24 capsid) for 6 hr and then infected with
HIV-1 (Vpr)/HSA (or luc) reporter virus, followed by analysis of HSA reporter expression; n = 2. Error bars represent ± SD for triplicate experiments.
(C) HIV-1 Vpr enhances induction of IL-6 expression in MDMs. Left panel: VSV-G pseudotyped HIV-lucDVpr vectors complemented with different Vpr mutants
were used to infect MDMs. Right panel: relative Vpr-enhanced IL-6 expression with MDMs derived from 6 donors is summarized by setting wild-type
Vpr-enhanced IL-6 expression at 1.0 (donor n = 6). Error bars represent ± SD for triplicate experiments.
(D) Vpr impairs the termination of IL-6 expression during HIV-1 infection. MDMs were infected with VSV-G pseudotyped HIV-lucDVpr complemented with
different Vpr mutants (donor n = 3). IL-6 mRNA levels were analyzed at indicated time points after infection. Error bars represent ± SD for triplicate experiments.
(E) TET2 genetic inactivation sustains IL-6 expression similarly to Vpr. VSV-G pseudotyped HIV-lucDVpr vectors complemented with WT or VprQ65R Vpr were
used to infect the Ctrl and TET2-KO cells, and mRNA level of IL-6 was determined; n = 3. Error bars represent ± SD for triplicate experiments.
(F) Vpr degrades TET2 and prevents recruitment of HDAC1 andHDAC2 to and enhances acetylation of the IL-6 promoter during resolution phase. THP1 cells were
infected with viruses followed by ChIP assays. Each ChIP DNA fraction’s Ct value was normalized to the IgG DNA fraction’s Ct value (DCt) at the same time point.
IgG is defined as 1. Error bars stem from three technical replicates; n = 2. Error bars represent ± SD for triplicate experiments.
(legend continued on next page)
phase (16–36 hpi) when compared to the cells infected with HIV-
luc+VprQ65R. In contrast, in TET2-KO THP1 cells, IL-6 expression
stayed high during resolution phase regardless of whether cells
were infected with HIV-luc+Vpr or HIV-luc+VprQ65R virus-like
particles. These data indicate that virion-associated Vpr sustains
IL-6 expression during resolution phase in a TET2-dependent
fashion.
To explore themechanism of Vpr-mediated persistent expres-
sion of IL-6, we performed ChIP-qPCR experiments to measure
the binding of IkBz, HDAC1, and HDAC2 to and histone acetyla-
tion of the IL-6 promoter in the parental and TET2-KO THP1 cells
at different time points after infection with HIV-luc+Vpr or HIV-
luc+VprQ65R viruses. Consistent with a previous report (Zhang
et al., 2015), IkBz bound to the IL-6 promoter at both early and
late phases during HIV-1 infection in both parental and TET2-
KO THP1 cells (Figure S4I). TET2 was not detected at IL-6 pro-
moter during early times of viral infection (4 hpi) but bound to
IL-6 later after viral infection (8 and 24 hpi), corresponding to
the resolution phase in cells expressing Q65R mutant Vpr (Fig-
ure 4F). Binding of TET2 to IL-6 promoter, however, was not de-
tected in THP1 cells infected with HIV-Luc-expressing wild-type
Vpr or in TET2-KO THP1 cells, supporting the specific binding of
TET2 to IL-6 promoter. HIV-1 infection did not change the protein
level of HDAC1 or HDAC2 (Figure S4J). Two HDAC proteins
bound to IL-6 promoter with distinct kinetics in THP1 cells in-
fected with HIV-Luc-expressing Q65Rmutant Vpr. HDAC1 bind-
ing to IL-6 promoter was nearly undetectable at early times of
viral infection, increased during the infection of HIV-Luc-ex-
pressing Vpr Q65R mutant, and reached its peak at the end of
the experimentation (24 hpi). Binding of HDAC2 to IL-6 promoter,
on the other hand, was readily detected prior to viral infection,
decreased to a background low level during early infection
(4 hpi), and rebounded later during the infection of HIV-Luc-ex-
pressing Vpr Q65R mutant (Figure 4F). Notably, binding of both
HDAC1 and HDAC2 to IL-6 promoter was substantially reduced
in THP1 cells expressing wild-type Vpr or in TET2-KO THP1 cells
(Figure 4F), indicating that TET2 is required for the binding of
both HDAC enzymes to IL-6 promoter. The level of H3 acetyla-
tion (H3Ac) in IL-6 promoter was increased initially in parental
THP1 cells, regardless of the genotype of Vpr, at 4 hpi and re-
mained relatively high in THP1 cells expressing wild-type Vpr
but was significantly reduced in cells expressing Q65R mutant
Vpr later during the infection. In TET2-KO THP1 cells, H3Ac
levels in IL-6 promoter were similarly increased following infec-
tion and stayed relatively high later during the infection regard-
less of the genotype of Vpr (Figure 4F). These results support
that transcription factor IkBz recruits TET2 to IL-6 promoter later
during the resolution phase, and TET2 in turn recruits HDACs to
promote the deacetylation and downregulation of IL-6 expres-
sion. Loss of TET2 function, resulting from either genetic deletion
or Vpr-promoted degradation, blocks HDAC recruitment to IL-6
promoter and leads to persistent IL-6 expression.(G) IL-6 contributes to Vpr-enhanced HIV-1 replication in macrophages. Left thre
donors treated with isotype control or anti-IL-6-neutralizing antibody. p24 levels 
ability of Vpr to enhance HIV-1 replication in cells treated with isotype control 
summarized by setting Vpr-enhanced replication in isotype control MDMs at 1.0. 
p values of < 0.05 and < 0.01, respectively.Finally, to test whether the elevated IL-6 is linked to Vpr-
enhanced HIV-1 replication, we infected MDMs with HIV-1 or
HIV-1DVpr viruses and then treated infected cells with either iso-
type control or IL-6-neutralizing antibody followed by measure-
ment of p24 in supernatant 6 days after infection. Vpr enhanced
p24 production an average of 17.2-fold in MDM cells from three
donors treated with isotype control antibody, but only 8.3-fold
in cells treated with IL-6-neutralizing antibody (Figures 4G and
S4K), indicating that elevated IL-6 contributes to 50% of the
enhancement of viral replication by Vpr. This result suggests
that Vpr degrades TET2 to enhance HIV-1 replication in part
through IL-6, and Vpr has an additional, IL-6-independent activ-
ity in facilitating HIV-1 replication.
DISCUSSION
The results presented here demonstrate that TET2 is an
inhibitor of HIV-1 replication and substrate of Vpr-hijacked
CRL4VprBP ligase. This conclusion is supported by two lines
of evidence. First, Vpr directly targets TET2 for polyubiquityla-
tion by the CRL4VprBP E3 ligase and subsequent degradation
by the proteasome. We demonstrated that Vpr-targeted degra-
dation of TET2 proteins requires Vpr-VprBP interaction, occurs
as early as 6 hr after infection in human cell lines as well as
primary cells, represents a conserved function of Vpr, and
can be sufficiently carried out by the Vpr protein incorporated
in the HIV virion particle. Second, we showed that overexpres-
sion of TET2 inhibited HIV-1 replication, and conversely, loss of
function of TET2 enhances HIV-1 replication in THP1 cells and
primary macrophages. Mutations in Vpr disrupting its binding
with VprBP abolished its ability to promote HIV-1 replication,
and this defect can be rescued by the deletion of TET2, directly
linking the function of Vpr in promoting HIV-1 replication
to TET2 degradation. Collectively, these results demonstrate
that TET2 is a restriction factor of HIV-1 and a major functional
target of Vpr.
IL-6 has long been reported to stimulate HIV-1 replication
in HIV-infected primary macrophages and is linked to enhanced
HIV-1 gene expression (Poli et al., 1990). Macrophages are a
main source of IL-6 during HIV infection and also a well-docu-
mented target cell for Vpr to enhance HIV-1 replication. Our
findings show that Vpr degrades TET2, thereby preventing it
from binding to and repressing IL-6 expression, which leads
to elevated IL-6 expression during resolution phase of inflam-
mation and is linked to the ability of Vpr to enhance viral repli-
cation. These results reveal a pathway for specific enhance-
ment of viral replication induced by Vpr in MDMs and provide
a molecular explanation for the persistent IL-6 and inflamma-
tion that have long been recognized as hallmarks of HIV-1
pathogenesis. These results also identify a target—Vpr-TET2-
IL-6 axis—for therapeutic intervention of HIV-1 infection and
inflammation.e panels: HIV-1 or HIV-1DVpr were used to infect MDMs from three different 
in the supernatant were measured at day 6 after infection. Right panel: relative 
and IL-6 blocking antibody at day 6 was calculated (donor n = 3). Data are 
Error bars represent the mean ± SD for triplicate experiments. * and ** indicate 
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Source of cell lines used in the study is reported in the Key Resources Table.
METHOD DETAILS
Plasmids
Expression constructs for TET proteins and VprBP were previously described (Nakagawa et al., 2015; Wang et al., 2015). Full-length
human TET2 cDNA (2,002 residues, NCBI reference number NP_001120680.1) was subcloned to the p3XFLAG-CMV destination
expression vector (Sigma-Aldrich). HIV-1 Vpr was also cloned into p3XFLAG-CMV destination expression vector. Point mutations
in TET2 (H1881Q) and Vpr (Q65R and R80A) were generated by site-directed mutagenesis and verified by DNA sequencing. The
C-terminal cysteine-rich, dioxygenase (CD) domain (residues 1128 - 2002) of TET2 (TET2-CD) was also cloned into p3XFLAG-
CMV and it consists of amino acid 1128-2002 of the full-length TET2. Vectors expressing HIV-1 Q23 Vpr, HIV-2 ROD9 Vpr, SIV-
mac239 Vpr, HIV-2 ROD9 Vpx and SIV-mac239 Vpx was a gift from Michael Emerman of University of Washington, Seattle. HIV-2
Vpx vector was a gift from Ronald Swanstrom of University of North Carolina at Chapel Hill and was cloned to a pcDNA3 vector.
Cell cultures and cell transfection
THP1 and HEK293T cells were purchased form UNC Lineberger Tissue Culture Facility. HEK293T cells were cultured in DMEM
containing 10% FBS and 1X Antibiotic-Antimycotic (Invitrogen). THP1 cells were maintained in RPMI 1640 medium containing
10% FBS, 1% Pen/Strep antibiotics, 2 mM glutamine, 10 mM HEPES and 1x non-essential amino acids (all from GIBCO). Human
buffy coats were obtained from Gulf Coast Regional Blood Center. Primary human peripheral blood mononuclear cells (PBMCs)
were isolated from buffy coats using Ficoll-paque gradient. PBMCs that are used for HIV-1 infection experiments were first activated
with CD3/CD28 activation beads (Thermo dynabeads) and IL-2 (300 U/mL) for 3 days, then maintained in 20 U/mL IL-2 during
experiments.
Primary monocytes were isolated from PBMCs using negative magnetic selection (EasySep Human Monocyte Isolation
Kit # 19359). Purified monocytes were seeded at a concentration of 1 3 106 cells/mL in complete RPMI, and differentiated into
Monocytes-Derived-Macrophages (MDM) using 50 ng/mL M-CSF and 50 ng/mL GM-CSF (Peprotech) for 6 days, changing medium
and cytokines every two days.
Transfection of 293Twas performed using lipofectamine 2000 (Invitrogen) followingmanufacturer’s protocol. Transfection of THP1
was performed using Amaxa Cell Line Nucleofector Kit V according to manufacturer’s protocol (Lonza VCA-1003). Briefly, 1 3 106
THP1 cells were incubated with 300 ng DNA in 100 mL nucleofector solution V, and immediately inserted into the nucleofector device
and use nucleofector program U-001. Transfected cells are cultured at 0.5 3 106 cells/mL for 24 hr, before use for further
experiments.
In vivo and in vitro ubiquitylation assay
In vitro ubiquitylation assays were performed as described previously (Nakagawa et al., 2015). Briefly, CUL4-VprBP immune
complexes were purified from HEK293T cells transfected with Flag-VprBP. Flag tagged VprBP was immunoprecipitated with anti-
FLAG M2 agarose beads for 3 hr in a NP-40 lysis buffer (0.3% Nonidet P-40, 50 mM Tris pH 7.5, 150 mM NaCl). Immobilized
Flag-VprBP complexes were washed three times in the same lysis buffer and eluted with an excess of Flag peptide (Sigma). Ubiq-
uitylation reactions were performed in a 50 mL reaction volume, containing 100 nM E1 (Enzo Life Sci.), 1 mM E2 (Enzo Life Sci.), 1 mM
human recombinant ubiquitin (Boston Biochem), 1 unit inorganic pyrophosphatase, 1 mM DTT and 5 mMMg-ATP, 100 ng of eluted
CUL4-VprBP complexes as the source of E3 and 100 ng of human Flag-TET2 as substrate. Reactions were incubated at 37C for 
30 min, terminated by addition of an equal volume of SDS sample buffer and resolved by SDS-PAGE.
For the in vivo ubiquitylation assay, HEK293T cells were transfected with indicated plasmids and siRNA for 48 hr, and were 
treated with MG132 (10 mM) for 5 hr before collecting the cells. Cells were lysed under denaturing conditions in a SDS buffer 
(50 mM Tris-HCl, pH 7.5, 0.5 mM EDTA, 1 mM DTT, 1% SDS) by boiling for 10 min. Lysate was clarified by centrifugation at 
13,000 rpm for 10 min and diluted 10-fold with an NP-40 buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.3% Nonidet P-40) and 
then subjected to immunoprecipitation by anti-Flag M2 agarose beads and subsequent SDS-PAGE. Ubiquitylated TET2 was 
detected with HA antibody.
RNAi, shRNA, and CRISPR-Cas9
All siRNA oligonucleotides were synthesized with 30 dTdT overhangs by Sigma in a purified and annealed duplex form. The 
sequences targeting each gene were as follows: human CUL4A, 50-GAACUUCCGAGACAGACCU-30; Human CUL4B, 50-AAGCCU 
AAAUUACCAGAAA-30; Human DDB1, 50-CCUGUUGAUUGCCAAAAAC-30; Human VprBP, 50-UCACAGAGUAUCUUAGAGA-30. For 
transfection of siRNA, OPTI-MEM medium (250 mL) was mixed with Lipofectamine 2000 reagent (Life Technologies, 10 mL) for 5 min 
and then incubated with another 250 mL OPTI-MEM medium containing 10 mL (20 mM) of siRNA for 20 min at room temperature. 
The mixtures were added to cells cultured on a 60-mm plate at 30%–40% confluence. The knocking down efficiency was determined 
48–72 hr after transfection.
pGIPZ-lentiviral vectors expressing control (non-targeting), TET2-targeting shRNA were purchased from Dharmacon, GE Health-
care (Lafayette, CO). shRNA targeting human TET2 has the mature antisense sequence: TAAGTAATACAATGTTCTT (clone ID: 
V3LHS_363201). Lentiviruses expressing GIPZ-shRNA were produced by CaCl2-BES transfection in 293T cells (10-cm plate) using 
15 mg pGIPZ-shRNA vector, 10 mg packaging construct DNRF and 5 mg pCMV-VSV-G. Lentiviruses were titered on 293T cells. Trans-
ductions of THP-1 cells were performed with a MOI of 0.5. For transduction of primary MDM, 50 ng of VLP-Vpx were first treated to 
4 3 105 cells MDM for 6 hr, then the cells were washed once with PBS and incubated with GIPZ-shRNA lentivirus (100 ng of p24). All 
lentiviral transductions were performed by adding 8 mg/mL polybrene, and spin inoculated with the cells for 2 hr, 1500 g at 37C. 
Transduced THP1 and MDM cells after 3 days were selected with 1-2 mg/mL puromycin for 3-7 days. The transduction efficiency 
was assessed by %GFP expression. All MDM donors presented in the data have achieved >90% transduction efficiency. TET2 
knockdown efficiency were subsequently measured by RT-qPCR.
CRISPR-Cas9 lentiviral vector lentiCRISPR v2 were purchased from Addgene. The gRNA sequence used for targeting TET2 is 
GATTCCGCTTGGTGAAAACG. Lentiviruses for CRISPR were produced by CaCl2-BES transfection of 293T cells (10-cm plate) using 
10 mg vector, 15 mg pMDLg/pRRE, 4 mg pRSV-Rev, and 5 mg pCMV-VSV-G. One million THP1 cells were transduced with 100 ng 
p24 of lentiviruses, and after 3 days selected with 2 mg/mL puromycin for 7 days. For single clone isolation of TET2-KO THP1, the pool 
of knockout cells was limiting diluted to 2 cells per well in 96-well plates, and the recovered KO clones were validated by DNA 
sequencing and western blot.
HIV-1 proviral constructs and virion stock production
NL4-3-HSA, NL4-3-HSA-R and NL4-LUC-ER proviral constructs expressing heat stable antigen (HSA) reporter or firefly 
luciferase reporter, respectively, were obtained from the NIH AIDS Reagent program. X4/R5 dual tropic HIV-1 NL4-R3A was gener-
ated by the Su lab as previously described (Meissner et al., 2004). Vpr mutant R3A was generated by insertion of heat stable antigen 
(HSA) reporter into the Vpr gene.
HIV-1 virions were produced by CaCl2-BES transfection of proviral plasmids in 293T cells. 293T cells cultured on a 10-cm plate 
were transfected with 30 mg DNA of pNL4-3 or pNL4-R3A for production of replication competent HIV-1 viruses, 25 mg pNL4-
LUC-ER with 5 mg pVSV-G for the production of VSV-G pseudotyped firefly luciferase reporter virus (HIV-LUC-G). For the produc-
tion of virus-like-particles (VLP) carrying Vpr or Vpr mutants, we transfected 293T with 6 mg p3XFLAG-CMV-Vpr, 15 mg pMDLg/pRRE, 
4 mg pRSV-Rev, and 5 mg pCMV-VSV-G. For the production of VLP-Vpx particles, we used a Gag/Pol expressing vector pMDL-X, 
containing the Vpx-packaging motifs in the p6 region, as described before (Bobadilla et al., 2013).
Virion stocks (both HIV-1 and VLPs) were harvested at 48 hr post transfection, and purified by ultra-centrifugation (20,000 g, 4C, 
2 hr). Concentrated particles were reconstituted with 1/10 times the amount of starting medium (i.e., resulting in 10x concentration 
of virus stocks). Concentration of virion stocks were quantified by p24 ELISA assay (Frederick National Laboratory for Cancer 
Research – AIDS and Cancer Virus Program).
HIV-1 infection
The titer of HIV-1 virion stocks was determined by infecting a known number of Jurkat T cells with titrated amount (p24) of virion par-
ticles, and evaluated by flow cytometry the percentage of infected cells (%p24 or %HSA) 2 days later. HIV-1 infection experiments 
were typically conducted at an MOI of 0.1, unless otherwise indicated in the figure legend. All HIV-1 infections were typically per-
formed in 96-well format (triplicates), by spin inoculation for 2 hr at 1500 g, 37C containing 8 mg/mL polybrene. Virus input are 
removed after spin inoculation, and fresh medium are added to infected cells. When indicated, anti-viral drugs sCD4 (10 mg/mL) 
T20 (5 mg/mL), Nevirapine (5 mM), Raltegravir (10 mM), or Amprenavir (5 mM) were added to the cells right before infection and main-
tained after infection.
Infections of freshly purified PBMCswith HIV-LUC-Gwere performedwith 10 ng p24 virus per 13 105 cells in 96-well format. Firefly
luciferase activity weremeasured at 48 hr post infection using Luciferase Assay System fromPromega and normalized to total protein
concentration. Infection with VSV-G pseudotyped VLP, VLP-Vpr or VLP-Vprmutant in THP-1 and PBMCs were performed using
500 ng p24 amount of VLPs per 1 3 106 cells by spin inoculation for 2 hr at 1500 g, 37C containing 8 mg/mL polybrene.
Flow cytometry analysis
HIV-1 infection efficiency was analyzed by HSA reporter expression or intracellular p24 expression at 48 hr post infection. For HSA
detection, surface antigen staining was performed in live infected cells with anti-mCD24-PE antibody (biolegend, 1:50 dilution in 2%
FBS PBS buffer) for 20 min. For intracellular p24 detection, infected cells were first permeabilized using Cytofix/cytoperm from BD
following manufacturer’s protocol, and then incubated with anti-p24-PE antibody (1:50 dilution, Beckman Coulter KC-57). Stained
samples were subsequently fixed in 1x formalin and analyzed with CyAn ADP (DAKO) or GUAVA ExpressPlus instrument. Cell-cycle
analysis was performed with genomic DNA staining by fixing cells with 75% ethanol at 20C overnight, followed by Propidium
Iodide staining of cellular DNA in 1% BSA containing RNase A. DNA levels were analyzed by FACS.
ChIP assay
For ChIP assay, cells were collected in an Eppendorf tube and resuspended in 7.5 mL cold PBS. Cellular proteins and DNA were
cross-linked by adding 0.5 mL of 16% formaldehyde into the tube (final concentration: 1%) and incubated at 37C for 15 min. Cells
were centrifuged at 1,000 rpm for 5 min and cell pellets were resuspended in 5 mL PBS buffer containing 0.125 M Glycine and
1X protease inhibitor cocktail (PIC). The cells were then incubated at room temperature with shaking for 5 min to quench unreacted
formaldehyde. The reaction was centrifuged and cell pellets were quickly rinsed with 10 mL of cold PBS and 1X PIC. Cells were
collected after centrifugation and transferred into a new Eppendorf tube with 1 mL cold PBS with 1X PIC, followed by centrifugation
at 1,000 rpm for 2 min to pellet the cells. Cell pellets were resuspended in 100 mL of SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM
Tris pH 8.1, 1X PIC) and incubated on ice for 15min. DNAwas sheared by sonication using a Covaris Sonicator (13 min at 4C). Insol-
uble material was removed by centrifugation at 12,000 g at 4C for 10 min. The supernatants were transferred to fresh tubes and
900 mL ChIP Dilution Buffer containing 1X PIC and 5 mL antibody or 20 mL fully resuspended anti-FLAG M2 Affinity Gel (Sigma)
was added to each tube. Mixtures were incubated overnight at 4C with rotation. Flag beads were precipitated by centrifuging at
2,000 rpm for 2 min at 4C. The bead-protein-chromatin complexes were washed in 0.5 mL each of the cold buffers in the following
order: (1) low Salt Wash Buffer, (2) high Salt Wash Buffer, (3) LiCl Wash Buffer, and (4) TE Buffer (all buffers fromMillipore). All washes
were performed by incubating complexes for 3-5 min with rotation followed by centrifuging at 2,000 rpm for 2 min. 100 mL of ChIP
Dilution Buffer and 1 mL proteinase K were then added into each tube, followed by two incubations, first at 62C for 2 hr and then a
second at 95C for 10min, both with constant shaking on an Eppendorf ThermoMixer (700 rpm). Samples were cooled down to room
temperature and centrifuged at 2,000 rpm for 2min at 4C. Supernatants were carefully transferred to a new tube containing 0.5mL of
Binding Reagent A. The sample-Binding Reagent A mixtures were transferred to the spin filter in the collection tube, centrifuged for
30 s at 12,000 g and decanted (this might be an easier way of saying pouring out supernatant). 500 mL ofWash Reagent Bwere added
to the same spin filter in the collection tube and centrifuged for 30 s at 12,000 g. The aqueous was carefully discarded, followed by
centrifugation for 30 s at 12,000 g. The spin filter was put into a new collection tube and 50 mL of Elution Buffer C (Millipore) was added
to the center of the spin filter membrane. After centrifugation for 30 s at 12,000 g, purified DNA was collected in the eluate for qPCR
analysis. IL-6 primers used for qPCR analysis of IL-6 promoter binding IkBz, TET2, HDAC1 and HDAC2 were as follows: Forward:
50-ACTTCGTGCATGACTTCAGC-30, Reverse: 50-AGTGCAGCTTAGGTCGTCAT-30.
QUANTIFICATION AND STATISTICAL ANALYSIS
All statistical analysis was performed with unpaired Student’s t test, and are considered significant when the p value is less
than 0.05. *, **, and *** indicate p values of less than 0.05, 0.01, and 0.001, respectively. n.s., not significant; N.D., not detected.
The number of times each experiment is repeated is indicated in the figure legends.
DATA AND SOFTWARE AVAILABILITY
Original imaging data have been deposited to Mendeley Data and are available at https://doi.org/10.17632/s77chxfn8t.1.
